ArticleFrontiers in public health2022

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.

Xia Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.